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Abstract
Background: Risperidone long-acting injection (LAI) is mostly administered twice weekly to people with
schizophrenia by nurses at community mental health centres (CMHC) or through mobile outreach visits. This study
estimates the cost of resource utilisation associated with the administration of risperidone LAI and the potential
savings from substituting two-weekly injections with a longer interval product of therapeutic equivalence.
Methods: A survey of mental health staff overseeing the administration of risperidone LAI at 253 distinct Australian
CMHCs was undertaken in November 2009. For the two-week period prior to the survey, respondents were asked
questions on injection time (and related tasks) and, for mobile outreach visits, distance and time travelled as well
as reduction in visits. Results were stratified by Australian Standard Geographical Classification (ASGC) region.
Resource use was quantified and valued in Australian dollars.
Results: Results are derived from 74 CMHCs, representing approximately 26% of the national average risperidone
LAI unit two-week sales. Stratified average injection time (including related tasks) for risperidone LAI ranged from
18-29 minutes, with a national average of 20.12 minutes. For mobile outreach visits, average distance per patient
ranged from 19.4 to 55.5 km for One Staff Visits and 15.2 to 218.1 km for More Than One Staff Visits, and average
time travelled ranged from 34.1 to 54.5 minutes for One Staff Visits and 29.2 to 136.3 minutes for More Than One
Staff visits. The upper range consistently reflected greater resource utilisation in rural areas compared to urban
areas. If administration of risperidone LAI had not been required, 20% fewer mobile outreach visits would have
occurred.
Conclusions: The national average saving per two-weekly risperidone long-acting injection avoided is $75.14. In
2009 in Australia, this would have saved ~$11 million for injection administration costs alone if all patients taking
two-weekly risperidone LAI had instead been treated with a therapeutically equivalent long-acting injectable
antipsychotic requiring one less injection per month.
Background
Australia’s First National Mental Health Plan promoted
the integration of inpatient and community services into
a cohesive mental health program [1]. This program
includes non-acute patients living in the community
receiving outpatient care provided predominantly by
local community mental health centres (CMHC) funded
through public hospitals [2]. In Australia, there are
nearly 6.4 million outpatient service contacts annually
involving 327,873 mental health patients at these ser-
vices [2]. The management of patients with schizophre-
nia and related disorders accounts for more than one-
third of these outpatient mental health service contacts
thereby placing a major burden upon mental health care
staff [2].
For a significant proportion of community dwelling
patients with schizophrenia, maintenance therapy com-
prises a long-acting injection of an antipsychotic medi-
cation administered during these outpatient visits. The
therapeutic options for these patients have recently
increased with therapeutically equivalent, but longer-act-
ing medication(s) becoming available [3]. A reduced
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any medium, provided the original work is properly cited.frequency of injections is likely to reduce the workload
of mental health care staff, however the need to receive
an antipsychotic medication is only one reason why they
may need to see a patient with schizophrenia. Thus a
reduced frequency of injections will not necessarily cor-
relate one-to-one with any reduction on the frequency
of consultations. Any economic evaluation of these new
products must therefore consider not only the value of
the resource savings per injection no longer required,
b u ta l s ot h en e ti m p a c tu p o nt h eo v e r a l lw o r k l o a do f
mental health care staff. In Australia, it has been
reported that the annual cost of schizophrenia to the
public health system is $841 million [4], or approxi-
mately $17,000 per patient [4,5]; literature searches
though did not identify any published estimates of the
resource use and non-medication costs attributable to
the administration of an antipsychotic either in Australia
or internationally. The Australian Department of Health
and Ageing has estimated the national average cost ‘per
occasion of service’ in outpatient psychiatric clinics of
public hospitals to be $276 [6], but these visits encom-
pass a broader range of services including general case
management and evaluation and do not include allow-
ance for mobile outreach visits.
In administering the injection of antipsychotic medica-
tions, CMHCs in Australia organise themselves indepen-
dently, adopting a variety of approaches that reflect
differences in the catchment populations. Patients may
receive their injection in their home or area of residence
(if homeless) if they are unwilling, or unable, to attend
their CMHC for their injection [2]. For the case-man-
agement of these patients, including their medication
needs, many CMHCs operate a mobile outreach service.
When an LAI is required at these outreach visits, case-
managers trained in alternative disciplines such as psy-
chology or social work, must be accompanied by a qua-
lified nurse who is eligible to administer injections. The
case-manager may also be accompanied by additional
colleague/s where a patient presents a security risk to
staff. Given the many competing demands upon com-
munity mental health staff, the task of administering
these injections is onerous, particularly as a significant
proportion of case-managers are not qualified to admin-
ister injections.
In addition to the cost of the medication itself,
resource use for injection administration typically
includes labour time of a registered nurse and related
tasks such as organising/scheduling an appointment
time, obtaining the prescription and medication, recon-
stituting the injection, and preparing the patient and
recording injection details in the patient medical file.
Importantly, these activities are required regardless of
whether administration of the injection occurs at the
CMHC or at a patient’s home. Mobile outreach visits
involve the additional costs of transport and travel time
for all staff attending.
This study estimates the resource use and associated
cost of administering an antipsychotic injection, and the
impact upon overall costs of the recent introduction of
a therapeutically equivalent, longer-acting (monthly),
alternative LAI antipsychotic [3]. The subject of the
study was risperidone LAI administered two-weekly; the
most commonly prescribed long-acting injectable anti-
psychotic in Australia. The results of this study may
also inform the resource burden and potential savings
for future funding and allocation of health care
resources.
Methods
We undertook a national survey of mental health pro-
fessionals responsible for administration of risperidone
LAI in the community setting. As it was anticipated that
the results of this study would most often be used in
economic studies as an estimate of cost-savings when
evaluating alternative approaches to clinical practice, a
conservative approach to cost-estimation was adopted.
A methodological complexity for this study was an
apparent lack of uniformity in appointment scheduling
at the CMHC and in the organisation, scale and staffing
policies of CMHC mobile outreach services. The most
common approach to scheduling appointments is for
those case managers at a CMHC who are qualified men-
tal health nurses to devote defined sessions each week
purely to administering injections. For the patient, the
injection appointment is usually distinct from their case
management appointments. Case-managers whose allied
health qualifications do not include nursing must
arrange a separate appointment time for their clients for
a case management session.
A further consideration in the methodological devel-
opment for this study was the anecdotal evidence that
the organisation and commitment of CMHCs to mobile
outreach services varied according to the geographic dis-
persion and diversity of patient population covered by
each clinic. For instance, a high proportion of forensic
or otherwise unstable patients have implications for the
need for additional staff to accompany the mental health
nurse administering the injection.
Survey Development
In order to obtain a broader understanding of the diver-
sity of organisational approaches to administering two-
weekly risperidone LAI and to ensure correct identifica-
tion in the survey of all resources utilised by CMHCs in
both metropolitan and regional areas, we consulted with
public psychiatrists including CMHC directors (n = 3)
and mental health staff located at CMHCs (n = 9). We
piloted our questionnaire with four mental health
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reached. The survey asked the respondent to recall how
many patients they had injected with risperidone LAI
over the two-weeks prior to completing the survey; the
amount of time spent administering risperidone LAI
(including related tasks of organising and scheduling the
appointment time, obtaining the prescription and medi-
cation, reconstituting the risperidone LAI, preparing the
patient for injection and recording administration details
in the patient’s file); whether more than one mental
health staff attended mobile outreach visits, as well as
the average distance and time travelled; and the fre-
quency of mobile outreach visits.
The survey also sought to quantify the reduction in
mobile outreach visits that might arise from administer-
ing a lower frequency of injections. Time and travel
costs may only be claimed as savings to the extent the
number of visits to patients is reduced. Participants
were asked how many mobile outreach visits would still
have occurred,e v e ni fa ni n j e c t i o no fr i s p e r i d o n eL A I
was not required. The framing of the question in this
way was considered to be important as a proportion of
visits would have still been appropriate for other rea-
sons. That is, when deciding whether a visit would still
have occurred, the survey questionnaire explicitly asked
participants to consider these reasons by listing exam-
ples including the need for counselling or other therapy
unrelated to the administration of risperidone LAI.
Furthermore, participants were asked to reflect upon the
actual cases they had seen over the previous two weeks
and provide responses in terms of numbers of visits
with and without the need for an injection. Inviting par-
ticipants to express the effect upon the frequency in this
form was thought to be less confounding, and less lead-
ing, than asking for results to be expressed as propor-
tional changes in the frequency of visits. Finally, as the
purpose of the survey was given as a study of injection
administration practice and costs, in order to minimise
any bias it did not provide any detail on how the results
may be used. The responses to this question enabled
estimates of the time and travel savings to be included
in the overall estimate of the non-medication savings (i.
e. excluding drug costs) from a reduced frequency of
injections.
Survey Administration
The authors obtained data on file from Janssen-Cilag
Pty Ltd. (the manufacturer of risperidone LAI), to iden-
tify all CMHCs in Australia who had placed an order
for risperidone LAI. Janssen-Cilag Pty Ltd has developed
the database over several years since risperidone LAI
was first registered for use in Australia. Surveys were
posted to all 253 CMHCs identified in these data. The
invitations were thus sent to the entire ‘population’ of
CMHCs known to have administered risperidone LAI at
some time, and therefore covered total use of the medi-
cation in Australia. The surveys were addressed to either
a named responsible mental health staff member(s)
where known and having previously consented to receiv-
ing survey requests, or to the “team leader” or “centre
manager” if specific contact details were not available.
However, if more than one survey was returned from
one CMHC, such survey(s) were excluded to avoid
“double-counting” and potential for over representation
of any one CMHC in the survey (Figure 1). Respondents
could either mail back their responses or respond online
using a “SurveyMonkey™” (http://www.surveymonkey.
com/) questionnaire that was otherwise identical to the
mailed format. Respondents were offered AUD $100 for
completing the survey.
Survey Analysis
Data from all questions were imported directly into
Excel (SurveyMonkey data) or entered via double-entry
(paper surveys). Respondents were contacted by tele-
phone to clarify invalid or incomplete responses. During
these telephone contacts, no quantitative or other lead-
ing information was provided in order to avoid leading
or otherwise biasing the responses.
Resource Valuation
Three patient treatment settings were identified for the
purpose of estimating resource use and the costing ana-
lysis: Setting 1: Administration of risperidone LAI for
patients attending a CMHC; Setting 2: Administration
of risperidone LAI at patient visits outside the CMHC
(mobile outreach visits) made by one mental health
staff; and Setting 3: Administration of risperidone LAI
at patient visits outside the CMHC by mobile outreach
visits made by two or more mental health staff
members.
Resource quantities were calculated for the following
variables: (i) labour time: time associated with adminis-
tering risperidone LAI including related tasks; and (ii)
additional resource utilisation for injections adminis-
tered outside the clinic, as in mobile outreach visits,
including travel time and distance travelled, number of
staff attending the visit ("One Staff” or “More Than One
Staff”) and the reduction (%) in the number of visits
required if a two-weekly injection of risperidone LAI
was no longer required (Figure 1).
The cost of these resources was then estimated. When
an injection is required, the main resource to be valued
is the time spent by a mental health nurse. The Federal
Government’s national schedule of fees for medical ser-
vices appears in the Medical Benefits Schedule (MBS).
The MBS lists the approved fees payable for approved
health care services by physicians and allied health
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cally for an intramuscular injection of an antipsychotic
by a mental health nurse. We estimated the cost of
labour for administering risperidone LAI based upon
our assessment of MBS item numbers for allied health
services (refer MBS schedule item numbers 81300 to
81360; available on line [7] which prescribe a fee of
$58.85 for a consult of at least 20-minutes for an allied
health professional service. Therefore, labour time (cost
per minute) was valued at $2.93 per minute derived as
$58.85 divided by the national average time for adminis-
tering an injection of 20.12 minutes as estimated from
the survey. As the prescribed fee of $58.85 is for a con-
sult of at least 20-minutes, the national survey result of
20.12 minutes was used to be consistent with the con-
servative approach adopted in the methodology. Since
the vial preparation, injection and directly related activ-
ities for each two-weekly injection of risperidone LAI
are the same regardless of whether the administration
occurs at the CMHC or outside the CMHC through a
mobile outreach visit, the average time for an injection
(and cost per minute) is a resource that applies equally
to all these patient treatment settings.
The cost per minute of labour time, $2.93 per minute,
was also used to value the average time travelled by
mental health staff to mobile outreach visits. The cost
per kilometre travelled during mobile outreach visits
was based on the cost of transport paid as reimburse-
ment to Federal public servants when using private vehi-
cles for official business [8] (the median value of $0.74
per kilometre). For mobile outreach visits involving
more than one staff member, it was conservatively
assumed that no more than 2 staff attended. For this
treatment setting, the injection and travel time costs for
both staff were included.
Cost Analysis
It was thought that organisational practices adopted by
CMHCs were likely to differ between rural and urban
areas. For example, a greater reliance on mobile outreach
p r o g r a m sw a sl i k e l yi na r e a sw i t hah i g hp r e v a l e n c eo f
homeless patients, and also in more remote areas. There-
fore, we anticipated that an inter-CMHC variation in
cost structures would exist. To account for this variation,
we identified an independent method of classifying geo-
graphic remoteness of each CMHC included in the evalu-
able data set of survey responses. This was achieved prior
to the cost analysis by stratifying survey responses based
upon geographical location (postal code) using the Aus-
tralian Bureau of Statistics (ABS) Australian Standard
Geographical Classifications (ASGC) [9]. The ASGC was
developed by the ABS for the collection and dissemina-
tion of geographically classified statistics, and comprises
of six regions: Major Cities of Australia; Inner Regional
Australia; Outer Regional Australia; Remote Australia;
Very Remote Australia; and Migratory. The last region
encompasses offshore, shipping and migratory census
collection districts, and was not used in our survey.
Costs were calculated by: (i) stratifying by ASGC
region and patient treatment setting; (ii) costing the
resource use by applying unit costs to attributable
labour time and travel estimates; (iii) determining the
average cost of resource use when weighted by the pro-
portion of total visits per patient treatment setting
within each ASGC region; (iv) calculating the reduction
(%) in home visits by ASGC region applied to one staff
Figure 1 Valuation of resources from the survey results.
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total costs in each treatment setting by summing steps
(iii) and (iv), weighting by the national risperidone LAI
unit sales per ASGC region (Figure 2, [10]). We con-
ducted a sensitivity analysis to assess the effect of
excluded responses on the primary analysis by including
responses from regional Australia that were originally
excluded to avoid “double-counting”.T h ed a t af r o m
these responses were included in the evaluable data set
and analysed using identical methods.
Results
Survey participants
We mailed surveys to 274 health professionals from all
253 identified CMHCs in Australia. Of these 27 (10%)
could not be delivered. We received responses from 93
(34%), of which 29 were received online, and 64 by mail.
We excluded 14 (15%) of the 93 responses of which 12
(13%) were due to multiple returns occurring from four
d i s t i n c tC M H C s ;o n e( 1 % )r e s p o n d e n td i dn o tp r o v i d e
name or contact details and therefore could not have
their responses stratified by AGSC, and another respon-
dent (1%) could not be contacted to clarify an incom-
plete response. Therefore, 79 of 274 surveys were
included in this analysis as evaluable responses - repre-
senting a 29% response rate from the known population
of CMHCs in Australia. These data are referred to as
the “evaluable data set”. All respondents comprising the
evaluable data set completed every question of the
survey.
Survey representativeness
Stratification by the evaluable data set by ASGC geo-
graphic region revealed a geographic distribution of the
79 responses that was consistent with both the national
survey list (n = 274, stratified by ASGC region) as well
Figure 2 Overview of the risperidone LAI cost of administration and cost analysis method.
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stratified by ASGC region; Figure 3, [10]). This analysis
confirms the national survey list and evaluable survey
population is representative of the community setting in
which risperidone LAI is administered nationally.
A so n l y7o ft h e7 9r e s p o n s e sw e r es t r a t i f i e dt ot h e
ASGC regions of ‘Remote Australia’ (5 responses) and
‘Very Remote Australia’ (2 responses), these were com-
bined for the presentation of results.
Data clarification
We successfully clarified 24 invalid or incomplete
responses.
Resource utilisation
The evaluable data set of survey respondents reported
information on 3,023 patients visits for the administra-
tion of risperidone LAI over a two-week period (Table
1). This equates to the administration of 3,203 units of
risperidone LAI, or 26% of the national average risperi-
done LAI unit sales over a two-week period (based
upon IMS national sales data for Risperidone Consta.
January - December 2009 [10]). Average injection time,
distance and time travelled for mobile outreach visits
are shown in Table 2. The upper range of injection
time, distance and time travelled reflect a greater
resource utilisation in rural areas compared to urban
areas. Also included in Table 2 are the respondents’
estimates of the reduction in visits that would have
occurred if an injection of risperidone LAI had not been
required. On average, respondents reported there would
have been 20% fewer mobile outreach visits if an injec-
tion was not required (Table 3).
Cost analysis results
The average cost per administration of a two-weekly
injection of risperidone LAI by ASGC region and
nationally is provided in Table 4. The national average
cost per administration of a two-weekly risperidone LAI
injection was calculated to be AUD $115.70 (Table 4).
Accounting for a 20% reduction in mobile outreach vis-
its should a two-weekly injection not be required (Table
4), the national average saving per two-weekly risperi-
done LAI injection avoided would be AUD $75.14 (95%
CI: $64.09 to $97.75) as shown in Table 5.
Sensitivity Analysis
To assess the effect of responses from regional Australia
w h i c hw e r eo r i g i n a l l ye x c l u d e dt oa v o i d“double-count-
ing”, the data from these responses were included in the
evaluable data set and analysed using identical methods.
The result was consistent with the primary analysis of
the evaluable data set, with only a slightly lower esti-
mate of the national average saving per two-weekly
injection avoided of $74.54 or $0.60 less than that
obtained in the primary result ($75.14).
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The aim of our study was to calculate the non-medica-
tion cost (i.e. excluding drug cost) of resource utilisation
per administration of risperidone LAI, and the average
saving per injection avoided that would be realised if
switching from a two-weekly injection to a four-weekly
therapeutically equivalent long-acting injectable antipsy-
chotic [3]. Whilst estimating the impact upon the fre-
quency of outreach visits was integral to the methods, an
implicit assumption is that other components of the care
provided to these patients remain constant. The clinical
experience of the authors suggests that this is a valid
assumption. Therefore, the estimate of $75.14 represents
the potential saving per administration of risperidone
LAI averted in the community outpatient setting in Aus-
tralia but can be applied in health systems internationally
where the approach to patient management is similar.
For instance, re-weighting of results to accommodate dif-
ferent levels of urbanisation can be approximated from
Table 1. From Table 2, local valuations can be derived
from the application of local unit costs.
We consider our survey to be representative of the ris-
peridone LAI patient population in Australia: the geo-
graphic distribution of the responses were similar to
both the distribution of CMHCs using risperidone LAI
and the geographic distribution of national risperidone
LAI unit sales; and the information collected (3,203 vis-
its involving a risperidone long-acting injection) cap-
tured approximately 26% of the two-weekly risperidone
LAI use in Australia (based upon 2009 unit sales).
Further, we conducted a sensitivity analysis which
confirmed that responses excluded from the evaluable
data set to avoid double-counting had a negligible
impact on the results of the primary analysis of the
national average saving per administration of risperidone
LAI avoided (i.e. only $0.60 difference).
Our approach also accounted for inter-CMHC varia-
tion due to geographic location, ensuring correct repre-
sentation of rural versus metropolitan settings by
stratifying responses for each CMHC based upon the
ASGC region. An alternative approach would be to
assume that each distinct CMHC responding was a
representative sample of all CMHCs administering ris-
peridone LAI in Australia, which would entail combin-
ing the data collected from each survey question and
assigning a monetary valued without stratification: an
approach which does not account for geographical
differences.
An important consideration in estimating the costs
directly attributable to risperidone LAI administration
involved recognition of the fact that mobile outreach
visits serve to monitor patient welfare and thus occur
for reasons other than merely to administer medication.
Therefore we did not assume that when switching from
a two-weekly to a therapeutically equivalent four-weekly
long-acting injectable antipsychotic that we could simply
halve the frequency of visits and therefore the cost. The
study accommodated this issue by asking respondents
how many of the patients in the two-week period of the
survey would still have been seen if they had not
Table 1 Patient treatment setting stratified by ASGC region
Patient Setting Major Cities Inner Regional Outer Regional Remote & Very Remote Total
Setting 1 Patients attending clinic 1,524 (72.3%) 346 (71.3%) 221 (77%) 101 (70.1%) 2,192 (72.5%)
Setting 2 Patients visited by 1 staff member 389 (18.5%) 99 (20.4%) 48 (16.7%) 28 (19.4%) 564 (18.7%)
Setting 3 Patients visited by > 1 staff member 194 (9.2%) 40 (8.2%) 18 (6.3%) 15 (10.4%) 267 (8.8%)
Total 2,107 (100%) 485 (100%) 287 (100%) 144 (100%) 3,023 (100%)
Note: one patient equates to the administration of one unit of risperidone LAI
Table 2 Summary of national average resource-utilisation per administration of a risperidone long-acting injection
Average Resource use ASGC region: Major
Cities (95% CI)
ASGC region: Inner
Regional (95% CI)
ASGC region: Outer
Regional (95% CI)
ASGC region: Remote &
Very Remote (95% CI)
Injection time (min) 19.4 (19.1 to 19.7) 18.2 (17.7 to 18.7) 23.4 (21.8 to 25.1) 29.0 (27.6 to 30.4)
National average injection
time (min)
20.12
Outreach visits 1 Staff
Visits
> 1 Staff
Visits
1 Staff
Visits
> 1 Staff
Visits
1 Staff
Visits
> 1 Staff
Visits
1 Staff
Visits
> 1 Staff
Visits
Distance travelled/Staff
(km)
22.9 (20.1 to
25.6)
19.2 (17.2 to
20.1)
19.4 (18.3 to
20.5)
19.5 (18. 3 to
23.1)
66.3 (43.2 to
89.4)
29.2 (15.5 to
42.9)
55.5 (12.7 to
98.2)
218.1 (12.7 to
331.8)
Time travelled/Staff (min) 44.6 (43.0 to
46.3)
41.4 (38.8 to
44.0)
34.1 (32.6 to
35.7)
33.4 (28.4 to
38.4)
54.4 (40.3 to
68.4)
29.2 (20.0 to
38.4)
54.5 (29.6 to
79.3)
136.3 (70.8 to
201.8)
Reduction in outreach
visits (%)
18.0 (0 to
40.3)
19.6 (0 to
49.6)
21.2 (0 to
58.1)
22.5 (0 to
70.9)
41.7 (4.0 to
79.0)
38.9 (0 to
100)
21.4 (0 to
67.6)
13.3 (0 to
100)
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these responses, the average proportional reduction in
visits could be more reliably estimated.
Limitations
A limitation of our survey was that the results are based
upon respondents’ recollections. To minimise recall
demands, the survey was restricted to a two-week period
prior to completion of the survey.
As staff were not aware of how the information was to
be used, and objective responses were required, the pay-
ment of $100 for providing a completed survey would
not have biased results. It did presumably contribute to
a high response proportion of 29%; much higher than
would normally be expected from a mail-out survey.
The methodological approach for this study was delib-
erately conservative. This impacts upon three compo-
nents of the survey. Firstly, it was assumed that no
more than two staff would attend visits. During the con-
sultation leading to the development of the survey, it
was evident that more than two staff attending would be
unusual with minimal impact upon results, yet to cap-
ture the small number of such cases in the survey
would have complicated the survey design with adverse
impacts upon both the quality of responses and overall
survey response rate. Secondly, the estimate of the cost
per minute of $2.74 for CMHC staff was based upon
the average time for an injection of 20.12 minutes to be
consistent with the MBS payment being for consulta-
tions of at least 20 minutes. Thirdly, and most impor-
tantly, it was not possible to quantify all costs possibly
related to the use of risperidone LAI specifically. For
instance, differences in storage requirements for refrig-
eration with risperidone LAI that is not a requirement
with other long-acting injectable antipsychotic(s) [3],
any impacts upon improved adherence, and resources
required for following up patients who do not attend
their 2-weekly appointments.
Therefore, the estimated cost per injection of risperi-
done LAI avoided in our study of $75.14 may underesti-
mate the full cost.
In Australia, increased government attention is being
given to improving services for people with mental ill-
ness and their families and carers through increasing
the clinical and health services available in the commu-
nity, including providing mental health nurses; and by
providing an increase in the mental health workforce
[11]. Longer-acting injectable antipsychotics would
release CMHC resources nationally in support of this
strategy.
Table 3 Summary of reduction in mobile outreach visits if an administration of risperidone long-acting injection was
not required (over a two-week period)
Average Resource use ASGC region:
Major Cities
ASGC region:
Inner Regional
ASGC region:
Outer Regional
ASGC region:
Remote & Very
Remote
Mobile Outreach Visits by CMHC staff 1 Staff
Visits
≥ 2 Staff
Visits
1 Staff
Visits
≥ 2 Staff
Visits
1 Staff
Visits
≥ 2 Staff
Visits
1 Staff
Visits
≥ 2 Staff
Visits
Mobile outreach visits (no.) 9.3 4.6 6.6 2.7 3.2 1.2 4.0 2.14
Mobile outreach visits still required if a risperidone LAI
administration was not required (no.)
7.6 3.7 5.2 2.1 1.9 0.7 3.1 1.86
Reduction in outreach visits (%) 18.0% 19.6% 21.2% 22.5% 41.7% 38.9% 21.4% 13.3%
National average reduction in mobile outreach visits if a
risperidone LAI administration was not required
20%
Table 4 Average cost of two-weekly administration of risperidone LAI (by ASGC region and nationally)
Total cost pert two-weekly injection of risperidone
LAI (Weighted)
a by ASGC region
ASGC region:
Major Cities
ASGC region:
Inner Regional
ASGC region:
Outer Regional
ASGC region: Remote &
Very Remote
Setting 1: Patients attending a clinic
b $41.03 $37.89 $52.83 $59.49
Setting 2: Mobile Outreach Visits (1 staff)
b $37.70 $34.16 $46.28 $55.46
Setting 3: Mobile Outreach Visits (> 1 staff)
b $33.76 $26.05 $20.66 $117.59
Total cost ($) by ASGC region (Cost Setting 1 + Cost
Setting 2 + Cost Setting 3)
$112.49 $98.10 $119.78 $232.53
National risperidone LAI unit sales weightings by
ASGC regions
62.4% 19.5% 14.0% 4.2%
National average cost per two-weekly injection $115.70
a the average injection time and related tasks associated with the administration of risperidone LAI is the same regardless of patient treatment setting
(attendance at a clinic or mental health staff visiting a patient outside the clinic)
b Weighted as the proportion of patient visits within each ASGC region
Dalton et al. BMC Health Services Research 2011, 11:236
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Less frequent injections saves resources, including time,
travel and reduced mobile outreach visits. The higher
cost of administration of a long-acting antipsychotic in
rural and remote regions is consistent with the greater
reliance upon mobile outreach visits in these settings.
The national average saving of AUD$75.14 per injection
avoided could potentially equate to a cost saving of
~AUD$11 million per year if all patients taking two-
weekly risperidone-long-acting-injection received instead
one less injection per month (based upon 2009
estimates).
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Table 5 Average saving per two-weekly administration of risperidone LAI avoided (by ASGC region and nationally)
Saving per treatment setting and ASGC region ASGC region:
Major Cities
ASGC region:
Inner Regional
ASGC region:
Outer Regional
ASGC region: Remote
& Very Remote
Setting 1: Patients attending a clinic
b $41.03 $37.89 $52.83 $59.49
Setting 2: Mobile Outreach Visits (1 staff) $15.37
a $15.79
a $25.98
a $24.84
a
Setting 3: Mobile Outreach Visits (> 1 staff) $15.01
a $12.65
a $13.30
a $30.99
a
Total Savings ($) by ASGC region (Savings Setting 1 +
Savings Setting 2 + Savings Setting 3)
$71.41 $66.33 $92.10 $115.33
National risperidone LAI unit sales weighted by ASGC region
(%)
b
62.4% 19.5% 14.0% 4.2%
Savings ($) from two-weekly visits avoided (Weighted) $44.55 $12.91 $12.88 $4.80
National average saving ($) per two-weekly injection
avoided
$75.14
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